Despite the decision to restrict coverage of Aduhelm, the Centers for Medicare and Medicaid Services (CMS) is not taking over FDA’s job as arbiter of which drugs ought to be licensed. It is simply doing a different job.
Does Medicare Draft Decision To Restrict Coverage Of Aduhelm Hold Lessons For Future Launches Of Drugs With No Proven Clinical Benefit?
